
    
      PRIMARY OBJECTIVE:

      I. To determine the safety and efficacy of propranolol hydrochloride (propranolol) in
      combination with standard neoadjuvant/definitive chemoradiation therapy (CRT) for esophageal
      cancer.

      SECONDARY OBJECTIVE:

      I. To estimate overall survival (OS) and pathologic response rate in patients that undergo
      surgery.
    
  